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Abstract
Background: Whilst multimorbidity is more prevalent with increasing age, approximately 30% of middle-aged adults
(45–64 years) are also affected. Several prescribing criteria have been developed to optimise medication use in older
people (≥65 years) with little focus on potentially inappropriate prescribing (PIP) in middle-aged adults. We have
developed a set of explicit prescribing criteria called PROMPT (PRescribing Optimally in Middle-aged People’s
Treatments) which may be applied to prescribing datasets to determine the prevalence of PIP in this age-group.
Methods: A literature search was conducted to identify published prescribing criteria for all age groups, with the
Project Steering Group (convened for this study) adding further criteria for consideration, all of which were reviewed
for relevance to middle-aged adults. These criteria underwent a two-round Delphi process, using an expert panel
consisting of general practitioners, pharmacists and clinical pharmacologists from the United Kingdom and Republic of
Ireland. Using web-based questionnaires, 17 panellists were asked to indicate their level of agreement with each
criterion via a 5-point Likert scale (1 = Strongly Disagree, 5 = Strongly Agree) to assess the applicability to middle-aged
adults in the absence of clinical information. Criteria were accepted/rejected/revised dependent on the panel’s level of
agreement using the median response/interquartile range and additional comments.
Results: Thirty-four criteria were rated in the first round of this exercise and consensus was achieved on 17 criteria
which were accepted into the PROMPT criteria. Consensus was not reached on the remaining 17, and six criteria were
removed following a review of the additional comments. The second round of this exercise focused on the remaining
11 criteria, some of which were revised following the first exercise. Five criteria were accepted from the second round,
providing a final list of 22 criteria [gastro-intestinal system (n = 3), cardiovascular system (n = 4), respiratory system
(n = 4), central nervous system (n = 6), infections (n = 1), endocrine system (n = 1), musculoskeletal system (n = 2),
duplicates (n = 1)].
Conclusions: PROMPT is the first set of prescribing criteria developed for use in middle-aged adults. The utility of these
criteria will be tested in future studies using prescribing datasets.
Keywords: Potentially inappropriate prescribing, Explicit criteria, Delphi technique, Middle-age, Polypharmacy,
Multimorbidity
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Background
Although a universal definition has yet to be adopted,
polypharmacy has conventionally been described as the
use of four or more medications [1]. A principal factor
contributing to polypharmacy is multimorbidity, which is
usually defined as the presence of two or more long-term
conditions [2]. As most long-term conditions are managed
by reference to separate evidence-based guidelines, the
lack of guidance on prioritising treatments in patients with
multiple conditions can lead to polypharmacy and is a
challenge for healthcare professionals [3]. One difficulty in
the prescribing for multimorbid patients is the risk of po-
tentially inappropriate prescribing (PIP), described as the
use of treatments which increase the risk of harm to a pa-
tient, or where a similar, or more effective alternative is
available which has a lower risk to the patient [4]. Concep-
tually, inappropriate prescribing encompasses a range of
behaviours for healthcare providers, including errors in
prescribing, over-prescribing, under-prescribing, cost ef-
fectiveness, non-adherence and alternative therapies [5].
Traditionally, the focus of PIP has been on older people
(defined as aged 65 years and above) due to the high
prevalence of medication use in this age group and age-
related changes in pharmacokinetics and pharmaco-
dynamics [6,7]. However, there is evidence that multimor-
bidity is also prevalent in middle-aged people (defined as
aged between 45 and 64 years) [2], but as yet, there has
been little consideration of PIP in this age group.
Prescribing tools have been developed to identify PIP
and may contain explicit or implicit criteria. Implicit cri-
teria are patient-specific and are designed for use with
clinical knowledge and judgement, but may be time-
consuming to use [7,8]. Explicit criteria are developed
from literature reviews, expert opinion and consensus,
require little or no clinical judgement, and can be ap-
plied to prescribing datasets in the absence of clinical in-
formation [7,8]. However, explicit criteria need regular
updates and may require adaption for use in other coun-
tries dependent on local guidelines and accepted clinical
practice [5]. Several explicit prescribing criteria have
been developed for application in older people to exam-
ine the prevalence of PIP and optimise prescribing
[9-16]. Explicit criteria have proven effectiveness in de-
termining the prevalence of PIP using population-based
data; for example, using a subset of the STOPP (Screen-
ing Tool of Older Person’s Prescriptions) and START
(Screening Tool to Alert doctors to Right Treatment)
screening tools, studies have shown an overall preva-
lence of PIP of 34% in Northern Ireland and 36% in the
Republic of Ireland among older people [17,18].
Published prescribing criteria for use in older people
often consist of a large number of criteria to be consid-
ered, and many of these criteria would be redundant in
people aged between 45–64 years due to the differences in
the prevalence of diseases and drugs used in these patient
groups, and changes in pharmacokinetics and drug metab-
olism associated with ageing [6,7]. We have identified the
need for a prescribing tool specifically for the middle-aged
population, containing criteria which are relevant for this
age-group. Such a tool may be used to determine the preva-
lence of PIP in middle-aged people and provide a quick and
easy-to-use resource for healthcare professionals. For this
reason, the present study aimed to develop the first set of
explicit prescribing criteria for middle-aged people called
PROMPT (PRescribing Optimally in Middle-aged People’s
Treatments) which could be applied to prescribing datasets,
independent of clinical information, to determine the
prevalence of PIP in middle-aged people.
Methods
Study design
A Delphi consensus technique was used to develop these
criteria. Delphi consensus allows an estimate of an overall
group opinion to be reached by improving agreement be-
tween a panel of experts through rounds of questionnaires
[19]. This process has been successful in the development
of previous explicit prescribing criteria for older people
[9-11,14]. Ethical approval for this study was obtained
from the School of Pharmacy, Queen’s University Belfast.
Compilation of initial criteria
The process used to develop the PROMPT criteria is out-
lined in Figure 1. We did not seek to undertake a system-
atic review of the literature relating to prescribing criteria
in older people. In order to inform the development of
PROMPT, commonly used prescribing criteria relating to
PIP in older people were identified by the Project Steering
Group (shown in Table 1). Using these sets of published
criteria, three members of the Project Steering Group (J.C.,
C.R. and C.H.) primarily considered the relevance of each
criterion to the target population. Criteria containing condi-
tions which are generally uncommon in middle-aged adults
(e.g. dementia) or containing medications currently unavail-
able in the United Kingdom or the Republic of Ireland were
excluded. Criteria which could not be applied in the ab-
sence of clinical information were also excluded. Following
these exclusions, a truncated list was reviewed by all mem-
bers of the Project Steering Group by a consensus discus-
sion. Members added further criteria for consideration that
arose during group discussion based on the clinical experi-
ence and expertise of the project steering group, for ex-
ample ‘mucolytic agents (e.g. carbocisteine, mecysteine)
should not be used routinely in stable chronic obstructive
pulmonary disease’. In this process, the Project Steering
Group considered many factors, including applicability of
the criterion in the absence of clinical information,
prevalence of drug use and the rationale for using a criter-
ion in middle-aged adults e.g. clinical relevance. Finally, the
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Project Steering Group also reviewed the prevalence of in-
dividual drug use in middle-aged adults using dispensing
data from the Enhanced Prescribing Database (EPD) and
the Primary Care Reimbursement Service (PCRS). The
EPD is a population-based dataset which stores information
on computer-generated prescriptions, issued in general
practice which have been subsequently dispensed by a com-
munity pharmacy in Northern Ireland. The PCRS stores in-
formation on all medications, and other health services,
provided without charge to people eligible for free medical
services via means testing and therefore is not representa-
tive of the entire population of Ireland. Potential criteria
containing medications with a low prevalence (i.e. to define
uncommon use, a cut-off of less than 0.5% was agreed by
the Project Steering Group) were excluded. Criteria were
also excluded if they were not applicable in the absence of
clinical information. For example, the criterion ‘Patients
with heart failure receiving a potassium sparing diuretic
(spironolactone) should not be prescribed a: non-steroidal
anti-inflammatory drug (NSAIDs), angiotensin converting-
enzyme inhibitor (ACE), angiotensin-II receptor antagonist
(ARB) or potassium supplement’ and the accompanying ra-
tionale ‘In patients with heart failure, the risk of hyperkalae-
mia is higher’ was removed by the Project Steering Group
during this screening stage as the criterion related specific-
ally to patients with heart failure and could only be success-
fully applied to a dataset with clinical information.
However, the Project Steering Group retained some criteria
which included reference to a specific clinical diagnosis as
it was still possible to apply these criteria to prescribing
Prescribing criteria screened by Steering Group (n=47)
Criteria added (n=4), criteria removed (n=18) and criterion divided in two (n=1) by Steering Group
Criteria included in first survey: (n=34)
Criteria accepted following the first 
survey (n=17)
Criteria reviewed by Steering Group following
the first survey (n=17)
Criteria included in second survey: (n=11)
The PROMPT criteria: (n=22)
Criteria removed by Steering Group
following review of additional comments
(n=6)
Criteria rejected following second survey: (n=6)
Figure 1 A flow chart for the development of the PROMPT criteria.
Table 1 Criteria screened for inclusion in PROMPT
Criteria name Origin Year Method
Beers Criteria [9] United States of
America
2012
update
Modified Delphi method
The PRISCUS List [10] Germany 2010 Delphi consensus technique
NORGEP Norwegian General Practice Criteria [11] Norway 2009 Delphi consensus technique
Basger Criteria [12] Australia 2008 Prescribing prevalence and review of drug
information
Winit-Watjana Criteria [13] Thailand 2008 Delphi consensus technique
STOPP Screening Tool for Older Person’s Prescriptions
[14]
Republic of Ireland 2008 Delphi consensus technique
START Screening Tool to Alert doctors to Right Treatment
[14]
Republic of Ireland 2008 Delphi consensus technique
Laroche Criteria [15] France 2007 Delphi consensus technique
McLeod Criteria [16] Canada 1997 Delphi consensus technique
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data without clinical information. For example, in the cri-
terion ‘Theophylline should not be used as monotherapy for
asthma or chronic obstructive pulmonary disease’ , a pre-
scription for an inhaled beta agonist, corticosteroid or mus-
carinic antagonist, a leukotriene receptor antagonist or
theophylline may be used as a proxy for other therapy for
asthma and COPD. Finally, some criteria identified from lit-
erature were modified by the Project Steering Group to
make them applicable to dispensing data (for example, we
defined long-term use as greater than three months’ dis-
pensed medicine).
Selection of the Delphi panel
Thirty specialists from the United Kingdom and Republic
of Ireland, recognised as experts in their fields, were
invited a priori (via e-mail) to participate in a Delphi con-
sensus panel to develop these criteria. Reasons for non-
participation by the experts were not sought, however the
most common explanation for a refusal was due to lack of
time. Of the 30 experts (who comprised experienced aca-
demic GPs, academic/clinical pharmacists and clinical
pharmacologists/physicians, identified by the Project
Steering Group) invited to join the panel, 17 agreed to
participate, and were representative of all specialists in-
vited to participate in terms of location and expertise.
Consent was received from all participating panel mem-
bers before commencing the process.
Data collection and analyses
The consensus process involved two rounds of web-
based questionnaires. The first questionnaire was piloted
(to test usability) by two members of staff in the School
of Pharmacy, Queen’s University of Belfast and modified ac-
cordingly. The first and second rounds of this development
process took place between July 2013 and September 2013,
and between October 2013 and November 2013, respect-
ively. For each of these rounds, panel members received a
link (via e-mail) to a questionnaire which was maintained
on an online survey software tool (SurveyGizmo®).
Reminders were sent to all panellists via e-mail to encour-
age completion of the exercise. The aims of the study were
explained to the panel members in the email, who were
asked to assess the applicability of each criterion to middle-
aged adults in the absence of clinical information. Panellists
were presented with statements and accompanying ratio-
nales, categorised by physiological systems (gastro-intestinal
system, cardiovascular system, respiratory system, central
nervous system, infections, endocrine system and musculo-
skeletal system) and a category for duplicate drug classes.
Panellists were asked to indicate their level of agreement
with each statement using a 5-point Likert scale [20] (where
1 was strongly disagree and 5 was strongly agree) and to
provide comments as necessary. Using this scale, the me-
dian response and the interquartile range were calculated
and the level required for consensus between the panel
members was decided prior to commencing the study.
When the upper quartile was ≤2, this indicated there was
general disagreement with the criterion between the panel
members, and the criterion was rejected. When the lower
quartile was ≥4, this indicated there was general agreement
with the criterion between the panel members, and the cri-
terion was accepted. When the interquartile range included
3, this indicated there was a lack of agreement between the
panel members and a need for further review of the par-
ticular criterion. Where the interquartile range included 3,
criteria were reviewed by Project Steering Group (via dis-
cussion) and were either revised and included in the second
questionnaire or rejected based on the additional com-
ments received from the panel members. Panellists did not
receive feedback from the first questionnaire. In the second
questionnaire, panellists were provided with a link to the
most recent guidelines supporting each criterion. As before,
the median response and the interquartile range were cal-
culated, and these measures of agreement (along with any
additional comments) were reviewed by Project Steering
Group. If consensus was not reached following the second
survey, the criterion (or part of the criterion in which there
was still disagreement) was rejected on the basis of the me-
dian response/interquartile range and the comments pro-
vided by the panel members.
Results
In total, 47 published prescribing criteria for older people
were screened by the Project Steering Group. Eighteen cri-
teria were removed by the Steering Group subject to the
pre-defined exclusion factors, four criteria were added
based on their own clinical experience and one criterion
was further divided into two criteria. Thirty-four criteria
were presented in the first round of this development
process, and all 17 panel members who agreed to partici-
pate in this Delphi exercise completed the questionnaire.
Group consensus (by overall agreement) was achieved for
17 criteria, which were accepted into the PROMPT criteria
(Table 2). No prescribing criteria were rejected following
the first round on level of agreement between Delphi panel
members. However, consensus was not reached on the
remaining 17 criteria. From these 17 criteria, 6 criteria were
rejected by the Project Steering Group following a review
of the respondents’ additional comments, leaving 11 criteria
for consideration in the second round of the Delphi con-
sensus exercise. The main reasons for exclusion of criteria
were the perceived need for clinical information, drug or
drug classes which were rarely seen in practice by the panel
members, lack of consensus and non-applicability to
datasets.
The second round of this developmental exercise was
completed by 15 of the 17 panel members who agreed
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Table 2 Outcomes from Delphi consensus exercises
First round Steering group consensus Second round Final set of criteria
Section Total Accepted Revision* Rejected Removal following first round Total Accepted Revision*¶ Rejected Total accepted
Gastro-intestinal system 4 1 3 0 1 2 1 1 - 3
Cardiovascular system 8 4 4 0 1 3 - - 3 4
Respiratory system 4 3 1 0 0 1 1 - - 4
Central nervous system 10 5 5 0 2 3 - 1 2 6
Infections 2 1 1 0 1 - - - - 1
Endocrine system 2 1 1 0 1 - - - - 1
Musculoskeletal system 3 1 2 0 0 2§ - 1 1 2
Duplicates 1 1 0 0 0 - - - - 1
Total 34 17 17 0 6 11 2 3 6 22
*Required revision, rewording or refinement ¶Required removal of part of criterion.
§The Project Steering Group moved one criterion to another section after the first round, this criterion was excluded in round two (changes not shown in table).
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to participate. We were unable to identify which mem-
bers had left the panel due to the anonymity of this exer-
cise, and therefore the reasons for non-participation in
the second round could not be obtained. Of the 11 cri-
teria in the second questionnaire, consensus was reached
in five criteria which were accepted into the PROMPT
criteria. The remaining six criteria were rejected follow-
ing a review of the level of agreement and additional
comments from the panel members. The main reasons
for exclusion of criteria following the second round were
the need for clinical information and lack of consensus
among panel members. Some exemplar comments re-
ceived from the Delphi Panel are shown in Table 3.
The final PROMPT criteria consisted of 22 criteria
organised over the following physiological systems:
Gastro-Intestinal System (n = 3), Cardiovascular System
(n = 4), Respiratory System (n = 4), Central Nervous Sys-
tem (n = 6), Infections (n = 1), Endocrine System (n = 1),
Musculoskeletal System (n = 2), Duplicates (n = 1). The
final set of criteria is presented Table 4.
Discussion
Using a Delphi consensus method, we have developed a
consensus-based set of prescribing criteria specifically
for use in middle-aged adults. PROMPT consists of 22
statements relating to potentially inappropriate use of
medications and has been developed for utilisation in
prescribing or dispensing datasets in the absence of clin-
ical information. The purpose of these criteria is for use
in determining the prevalence of PIP in datasets contain-
ing information on dispensed medications (and may
therefore serve as a proxy for prescribing quality) by
adopting epidemiological approaches, but also for use as
part of a screening approach in clinical practice. In pri-
mary care, healthcare professionals such as community
pharmacists may not have access to medical records in-
cluding diagnosis, and the PROMPT criteria may be a
resource in this setting. The PROMPT criteria could also
be used by pharmacists to perform medication reviews
or to check dispensing queries when issuing medications
to middle-aged adults with multimorbidity. Finally, as
continuity of care has been highlighted as an issue for
people living with multimorbidity who have higher con-
sultation rates [23], coupled with the fragmentation of
care, the PROMPT criteria may be used to identify areas
where the greatest PIP burden lies and assist in targeting
an intervention, such as a clinical decision support sys-
tem (CDSS). With this in mind, PROMPT was not de-
veloped as an exhaustive list for PIP in middle aged
adults. Instead, these criteria represent a list of com-
monly prescribed medications in the United Kingdom or
the Republic of Ireland which may be used to explore
the PIP burden, and factors associated with PIP such as
age, gender and polypharmacy in this age group via
descriptive studies using prescribing or dispensing data-
bases. Following the development of these criteria, the
utility and validity of PROMPT will be tested in future
studies using national prescription-based databases.
PROMPT may be used in other countries by researchers,
but may require translation, and some modifications
based on country specific prescribing guidelines, clinical
practice and drug formularies [5].
Using the Delphi consensus method, the panel mem-
bers informed the development of these criteria through
their level of agreement and additional comments. Fur-
thermore, the revisions to the criteria following each
consensus round were based on comments received
from the panel members. Some criteria were rejected as
panel members were concerned that clinical information
would be required to successfully apply the criteria.
Other issues from panellists included difficulties in de-
termining the appropriateness of a prescribed medica-
tion without knowledge of whether a treatment had
been initiated by a specialist or if therapy was being cor-
rectly monitored (for example, via regular laboratory
tests). Therefore, medications which may be prescribed
primarily in specialty care settings have not been in-
cluded. An attempt will be made to address these issues
in future versions of the PROMPT criteria by incorporat-
ing clinical information and drug monitoring. Panel
members were also concerned that although they may
agree with a criterion in principle, they found that it did
not fit with standard clinical practice or other influences.
For example, in the criterion which stated ‘stimulant
laxatives (e.g. bisacodyl, senna) should not be used long-
term i.e. for greater than four weeks’ regular prescribing
of some drug classes such as laxatives may be dictated
by patient demand.
Strength and limitations
This study has several key strengths. Firstly, the
PROMPT criteria were constructed from two sources
(clinical experience of the Project Steering group and
from a review of published sets of criteria for older
people) incorporating criteria across a range of physio-
logical systems. Some criteria included in PROMPT
were identified in many of the existing prescribing tools
for older people (Table 1). However, the STOPP screen-
ing tool was the most commonly cited set of prescribing
criteria, showing some overlap with these sets of criteria.
Other criteria frequently cited in PROMPT were the
Beers criteria (n = 9), Laroche criteria (n = 8) and NOR-
GEP Norwegian General Practice criteria (n = 8)
[9,11,15]. Second, references to prescribing guidelines
were not provided in the first questionnaire, but were
supplied for the second questionnaire, at the request of
the Delphi panel. This allowed an informed decision
(after considering relevant guidelines) to be made by the
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Table 3 Exemplar comments received from the Delphi panel
Section Gastro-intestinal section Respiratory section
Example of statement
used in Round 1
Stimulant laxatives (e.g. bisacodyl, senna) should not be
used long-term i.e. for greater than four weeks.
First generation antihistamines (e.g. chlorphenamine,
promethazine) should not be used for greater than
seven days.
Rationale: Stimulant laxatives are not suitable for long-term use
(greater than four weeks), due to risk of dependency and
decreased bowel function.
Rationale: First generation antihistamines exert
anticholinergic properties causing unwanted side-effects
e.g. constipation, drowsiness, psychomotor impairment.
Comments from
Round 1*
C1: Chronic management sometimes required. C1: Addiction is a problem with these agents.
C4: Regular Prescribing often led by patient demand. C3: Depends on indication, alternatives tried and their effect.
Certainly not first line.
C5: Lack of evidence base regarding effect on long term bowel
function, old case reports likely consequent to adulteration in
laxative preparation.
C4: Often led by patient demand. but most likely will be on
2nd generation antihistamine.
Revisions made for
Round 2 (revisions
shown in bold text)
Stimulant laxatives (e.g. bisacodyl, senna) should not be
prescribed as first-line treatment in constipation for
greater than four weeks (other than for opioid induced
constipation).
First generation antihistamines (e.g. chlorphenamine,
promethazine) should not be used as first-line agents
for greater than seven days.
Rationale: Stimulant laxatives are not suitable for continuous
long-term use, other than for opioid induced constipation.
Rationale: First generation antihistamines may cause
addiction and/or exert anticholinergic properties causing
unwanted side-effects e.g. constipation, drowsiness,
psychomotor impairment.
Comments from
Round 2*
C1: Stimulants are only licenced for short term use, but the
guidance you steer us to does not say anything that comes
close to the indicator in terms of “should not be prescribed”, so
I don’t think it’s a sensible indicator (I’d be happier to support
one about “should use” stimulants in people on strong opioids).
C1: You would only continue using them if the patient either
didn’t respond to other antihistamines and/or didn’t have
any of the above side effects- I have seen plenty of patients
who are fully function on full dose chlorphenamine. Of
course, they can buy it OTC so I guess there are lots of
people out there who (we hope) are fine and using it.
C2: However we recognise that some patients will buy these
products and/or may be using them without health professional
knowledge or advice. Best practice is to review after four weeks
and reassess for alternatives.
C2: Especially for hypnotic indications.
C3: Bulk forming or osmotic laxatives should be used first.
Conclusion Further rewording following Round 2. Final statement: No further revision following Round 2. Final statement:
Other than for opioid-induced constipation, stimulant laxatives
(e.g. bisacodyl, senna) should not be prescribed as first-line
treatment in constipation for greater than four weeks.
First generation antihistamines (e.g. chlorphenamine,
promethazine) should not be used as first-line agents
for greater than seven days.
Rationale: Stimulant laxatives are not suitable for continuous
long-term use, other than for opioid induced constipation.
Rationale: First generation antihistamines may cause
addiction and/or exert anticholinergic properties causing
unwanted side-effects e.g. constipation, drowsiness,
psychomotor impairment.
*Please note, this is only a selection of comments used in the revision of exemplar criteria to convey the views of the Panel and how criteria were subsequently revised.
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Table 4 The PROMPT criteria
Original source(s)
for criteria
Section Rationale
Gastro-Intestinal System
[15] Other than for opioid-induced constipation, stimulant laxatives
(e.g. bisacodyl, senna) should not be prescribed as first-line
treatment in constipation for greater than four weeks.
Stimulant laxatives are not suitable for continuous
long-term use, other than for opioid induced
constipation.
[14] Proton pump inhibitors (PPIs) (e.g. esomeprazole, omeprazole)
should not be prescribed at doses above the recommended
maintenance dosage for greater than eight weeks.
A dose reduction or discontinuation is indicated since
there is no therapeutic benefit observed with the use
of higher doses of PPIs long-term (unless treatment
is indicated for rare conditions e.g. Zollinger-Ellison
syndrome).
Added by Project
Steering Group [21]
Esomeprazole or omeprazole should not be used in
combination with clopidogrel.
Esomeprazole and omeprazole may reduce the
anti-platelet effect of clopidogrel and therefore s
hould not be used in combination with clopidogrel.
Other proton pump inhibitors or H2-receptor
antagonists are available which do not have the
same potential for interaction.
Cardiovascular System
[9,10,13] The use of alpha-adrenoceptor blocking drugs (e.g. doxazosin,
prazosin) as monotherapy for hypertension, should be avoided.
Alpha-adrenoceptor blocking drugs increase the risk
of orthostatic hypotension.
[14] Aspirin doses should not exceed 150 mg/day for anti-platelet
therapy.
Doses exceeding 150 mg/day show no evidence for
increased efficacy and will increase the risk of
bleeding.
[11,14] Cardio-selective calcium-channel blockers (e.g. verapamil,
diltiazem) should not be used in combination with beta-
adrenoceptor blocking drugs.
Concomitant use increases the risk of atrioventricular
block and myocardial depression.
[9,14-16] The use of oral short-acting dipyridamole should not be used
as monotherapy in antiplatelet treatment.
Oral short-acting dipyridamole may cause orthostatic
hypotension; more effective alternatives available.
Respiratory System
[9-11,14,15] First generation antihistamines (e.g. chlorphenamine,
promethazine) should not be used as first-line agents for
greater than seven days.
First generation antihistamines may cause addiction
and/or exert anticholinergic properties causing
unwanted side-effects e.g. constipation, drowsiness,
psychomotor impairment.
[11,14] Theophylline should not be used as monotherapy for asthma
or chronic obstructive pulmonary disease.
Theophylline is associated with an increased risk
of arrhythmias.
[14] A concomitant bisphosphonate should be prescribed if oral
corticosteroids are used long-term (greater than three months).
Long-term use of an oral corticosteroid increases the
risk of osteoporosis and subsequent bone fracture.
Added by Project
Steering Group [22]
Mucolytic agents (e.g. carbocisteine, mecysteine) should not be
used routinely in stable chronic obstructive pulmonary disease.
There is little benefit from the use of mucolytic agents
in stable chronic obstructive pulmonary disease.
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Table 4 The PROMPT criteria (Continued)
Central Nervous System
[12] Selective serotonin reuptake inhibitors (e.g. citalopram,
fluoxetine) should not be used in combination with venlafaxine.
Concomitant use may lead to the development of
serotonin syndrome.
[9-13,15] Tricyclic antidepressants (TCAs) (e.g. amitriptyline, nortriptyline)
should not be used as first-line in treatment of depression.
TCAs are associated with unwanted peripheral
anticholinergic side-effects e.g. constipation, dry
mouth and central anticholinergic side-effects
e.g. drowsiness.
[9-16] Benzodiazepines (e.g. nitrazepam, temazepam) should not be
used long-term (greater than four weeks).
Long-term use of benzodiazepines increases the risk
of dependency. Benzodiazepine related adverse
effects include daytime sedation, cognitive
impairment, agitation, irritability.
[9,10] Non-benzodiazepine hypnotics (zolpidem, zaleplon, zopiclone)
should not be used long-term (greater than 4 weeks).
Non-benzodiazepine hypnotics have adverse events
similar to those of benzodiazepines with minimal
improvement in sleep latency and duration.
[11] Carbamazepine should not be used in combination with
clarithromycin or erythromycin.
Clarithromycin and erythromycin inhibit the
metabolism of carbamazepine therefore increasing
the risk of adverse effects e.g. headache, drowsiness,
nausea.
[12,14] Strong opioids (e.g. buprenorphine, diamorphine, fentanyl,
morphine, oxycodone) should not be prescribed without the
co-prescribing of laxatives.
Strong opioids are likely to cause constipation.
Infections
[9,10,15] Nitrofurantoin should not be prescribed for greater than 7 days
for the management of uncomplicated lower urinary-tract infections.
Potential for pulmonary toxicity; safer alternatives
available.
Endocrine System
[9,14,15] In relation to the management of diabetes, the use of oral
long-acting sulfonylureas (glibenclamide) should be avoided.
Oral long-acting sulfonylureas have a prolonged
half-life and can cause prolonged hypoglycaemia
or syndrome of inappropriate antidiuretic hormone
(ADH) secretion.
Musculoskeletal System
[9,10,13,14,16] Non-steroidal anti-inflammatory drugs (NSAIDs) (e.g. celecoxib,
diclofenac, naproxen) should not be used long-term (greater than
three months).
Long-term NSAID treatment should be reviewed
periodically due to increased risk of thrombotic effects,
and the lowest effective dose should be prescribed for
the shortest period.
[11-13] Unless adequate gastro-intestinal protection is provided with either
a proton pump inhibitor or H2-receptor antagonist, non-steroidal
anti-inflammatory drugs should not be used in combination with:
Concomitant use increases the risk of gastro-intestinal
bleeding.
a. Low-dose aspirin.
b. Selective serotonin re-uptake inhibitors.
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Table 4 The PROMPT criteria (Continued)
Duplication of drug classes
[11,12,14,15] The use of two or more drugs from the same pharmacological class
should be avoided, unless used for additive effects in line with
current clinical guidelines.
Possible unwanted duplication of effect, increasing
risk of side effects and adverse events.
For example: Avoid duplication of opioid analgesics, non-steroidal
anti-inflammatory drugs, benzodiazepines.
An example of an exception includes: duplicate beta2
agonists (provided one is short-acting and one is
long-acting) for the management of asthma or
chronic obstructive pulmonary disease.
C
ooper
et
al.BM
C
H
ealth
Services
Research
2014,14:484
Page
10
of
13
http://w
w
w
.biom
edcentral.com
/1472-6963/14/484
panellists for criteria where there was a lack of consen-
sus. Third, the Delphi panel responsible for screening
the criteria consisted of a heterogeneous group of ex-
perts, who all consented to participate prior to the first
round of the questionnaire being distributed. Further-
more, this panel of experts represented a range of disci-
plines from geographically diverse areas of the United
Kingdom and the Republic of Ireland, making the expert
group representative of healthcare professionals involved
in the care of our target population. Fourth, the number
of rounds and consensus method was decided in ad-
vance of the questionnaire distribution, with criteria ac-
cepted or rejected following pre-defined instructions.
Finally, panellists were not provided with feedback fol-
lowing each round of the development exercise, there-
fore removing any potential bias of panellists modifying
their own responses to match those of the groups.
As with all developmental studies for PIP criteria which
use a Delphi exercise, there are associated limitations.
These include the potential lack of reproducibility as re-
sults may be dependent on the experts chosen for the Del-
phi panel [24]. We attempted to limit this potential bias
by inviting a heterogeneous group of panel members to
participate in this exercise. Other limitations include the
lack of accountability for responses in the use of anonym-
ous surveys and the lack of responses from panellists
within increasing rounds which can cause bias [24]. It was
intended that the use of anonymous surveys would mean
panellists were not influenced by other members of the
panel or the Project Steering Group. This did have a dis-
advantage, since the questionnaire responses could not be
linked to any one individual, we were unable to identify
members of the group who did not complete the second
questionnaire. Therefore, a reminder was issued to all
members of the Delphi panel to complete each round of
the questionnaire. The second round questionnaire was
completed by 15 of the 17 panel members who partici-
pated in the first round. However, this level of dropout
among panellists is common in other developmental stud-
ies for PIP criteria [11]. Finally, these criteria will require
future validation against healthcare outcomes such as hos-
pitalisation or mortality.
Comparison with existing literature
A recent review of published criteria has examined many
aspects of inappropriate prescribing, including errors in
prescribing, over-prescribing, under-prescribing, cost in-
effectiveness, non-adherence and alternative therapies
[5]. Most of the criteria included in PROMPT address
PIP associated with the over-prescribing of medications
in middle-aged adults. However, some criteria in
PROMPT address under-prescribing or omissions. For
example, ‘A concomitant bisphosphonate should be pre-
scribed if oral corticosteroids are used long-term (greater
than three months)’ with the supporting rationale ‘Long-
term use of an oral corticosteroid increases the risk of
osteoporosis and subsequent bone fracture’. The START
screening tool can be used to measure medication omis-
sions in older age adults [14]. A future version of
PROMPT which includes all aspects of PIP may provide
further resources for assessing the burden of PIP in this
age-group and support more comprehensive clinical
medical reviews.
To date, there has been little consideration of PIP in
middle-aged adults, although recent evidence has sug-
gested that multimorbidity is prevalent in middle-aged
people [2]. A recent cross-sectional study, which included
over 1,750,000 people registered with 314 medical prac-
tices in Scotland, found that 30% of people aged between
45 and 64 years had multimorbidity [2]. This study
highlighted the link between multimorbidity and increas-
ing age, socioeconomic deprivation, mental health disor-
ders (particularly depression) and gender [2]. The
increasing prevalence of multimorbidity in middle-aged
adults may also have economic implications. A retrospect-
ive observational study using data from the Clinical Prac-
tice Research Datalink (formerly known as the General
Practice Research Database) investigated the burden of
multimorbidity on primary care resources in a cohort of
over 86,000 patients aged 20 years and over in the United
Kingdom [25]. In all age groups, estimated prevalence-
adjusted costs (including consultations, prescribed medi-
cation and tests) showed that patients living with any two
conditions of depression, obesity, diabetes or asthma were
associated with the greatest cost effect [25]. Considering
this emerging evidence, studies aimed at determining the
prevalence of PIP using the PROMPT criteria may identify
important patterns in the prescribing of medications in
middle-aged adults with multimorbidity and provide some
evidence of the level of economic burden associated with
PIP in this age-group. PROMPT may also identify areas to
improve the quality of life in this age-group. A cross-
border study in Ireland which analysed over 6000 adults
aged 50 years and over [data from the 2007 Survey of Life-
style, Attitudes and Nutrition in Ireland (SLAN) and the
2005 Northern Ireland Health and Social Wellbeing Sur-
vey (NIHSWS)] found that people living with multimor-
bidity were at the greatest risk of disability, poor self-rated
health and reduced quality of life [26]. PROMPT may
therefore have a role in investigating the independent ef-
fects between PIP, polypharmacy, multimorbidity and
quality of life health outcomes in future quantitative and
qualitative studies.
Conclusions
Using a Delphi consensus method, we have developed the
first set of prescribing criteria specifically for use in middle-
aged adults. The PROMPT criteria may be applied to
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prescription-based datasets in the absence of clinical infor-
mation to determine the prevalence of PIP, and the utility
of these criteria will be tested in future studies using pre-
scribing datasets.
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